PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1536.00 - 1565.00
1090.00 - 1784.00
46.2K / 155.6K (Avg.)
23.48 | 66.41
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
10.35%
Positive revenue growth while 5715.T is negative. John Neff might see a notable competitive edge here.
-3.36%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-38.35%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-18.20%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-55.37%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-55.32%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-55.32%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
-0.00%
Share reduction while 5715.T is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-93.11%
Both companies have negative long-term revenue/share growth. Martin Whitman would question if the entire market or product set is shrinking.
-26.07%
Both face negative 5Y revenue/share CAGR. Martin Whitman would suspect macro headwinds or obsolete product offerings across the niche.
-7.29%
Both firms have negative 3Y CAGR. Martin Whitman would wonder if the entire market segment is in short-term retreat.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
92.77%
Similar net income/share CAGR to 5715.T's 94.22%. Walter Schloss would see parallel tailwinds or expansions for both firms.
-2690.48%
Negative 5Y net income/share CAGR while 5715.T is 79.06%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-152.21%
Negative 3Y CAGR while 5715.T is 13.05%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
No Data
No Data available this quarter, please select a different quarter.
52.20%
5Y equity/share CAGR is in line with 5715.T's 56.31%. Walter Schloss would see parallel mid-term profitability and retention policies.
35.88%
3Y equity/share CAGR 1.25-1.5x 5715.T's 25.55%. Bruce Berkowitz confirms timely buybacks or margin improvements drive stronger near-term equity growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-20.62%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
12.04%
Inventory growth well above 5715.T's 18.36%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
1.21%
Positive asset growth while 5715.T is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
-3.64%
We have a declining book value while 5715.T shows 1.84%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
9.70%
We have some new debt while 5715.T reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
-100.00%
Our R&D shrinks while 5715.T invests at 0.00%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
2.92%
SG&A growth well above 5715.T's 5.61%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.